{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-111665","form_type":"8-K","ticker":"LIMN","cik":"0001971387","company_name":"Liminatus Pharma, Inc.","filed_at":"2026-09-29T13:15:22+00:00","discovered_at":"2026-09-29T13:16:00.249854+00:00","generated_at":"2026-10-12T13:44:12.721038+00:00","sec_items":["3.01","7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Liminatus Pharma regains Nasdaq minimum bid price compliance after 1-for-50 reverse split","bullets":["Nasdaq notice dated Sept 24, 2026: closing bid price was above $1.00 for 13 consecutive trading days from Aug 21 to Sept 9, 2026; the matter is now closed.","Company effected a 1-for-50 reverse stock split at the close of trading on Aug 20, 2026 to cure the bid price deficiency.","Original Jan 15, 2026 notice: bid below $1.00 for 30 consecutive business days, failing Nasdaq Listing Rule 5450(a)(1) for the Global Market.","Nasdaq Hearings Panel transferred the company to the Nasdaq Capital Market effective Aug 4, 2026 and set a Sept 3, 2026 deadline under Rule 5550(a)(2)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-111665","json":"https://secwatch.observer/filing/0001104659-26-111665.json","markdown":"https://secwatch.observer/filing/0001104659-26-111665.md","text":"https://secwatch.observer/filing/0001104659-26-111665.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926111665/0001104659-26-111665-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926111665/tm2626488d1_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T13:44:12.721038+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}